Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab, Cetuximab beta, and Irinotecan in HER2+ mCRC
NCT07059338Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab, cetuximab in metastatic colorectal cancer (mCRC), sponsored by Sun Yat-sen University. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
trastuzumabcetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07059338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07059338.